Navegando por Palavras-chave "colitis, ulcerative"

Agora exibindo 1 - 2 de 2
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Anticorpo anticitoplasma de neutrófilos (ANCA) em pioderma gangrenoso, um marcador sorológico para associação com doenças sistêmicas: estudo de oito casos
    (Sociedade Brasileira de Dermatologia, 2004-02-01) Cabral, Virgínia Lúcia Ribeiro [UNIFESP]; Miszputen, Sender Jankiel [UNIFESP]; Catapani, Wilson Roberto; Universidade Federal de São Paulo (UNIFESP); Faculdade de Medicina do ABC
    BACKGROUND: The pathogenesis of Ulcerative Colitis (UC) and its extraintestinal manifestations remain uncertain, although involvement of the immune system is emphasized. The likely importance of neutrophils is demonstrated by detection of the antineutrophil cytoplasmic antibody (ANCA) in this inflammatory bowel disease. Pyoderma Gangrenosum (PG) is an idiopathic skin condition and a rare cutaneous manifestation of UC. ANCA has also been reported in the latter dermatosis. OBJECTIVES: To invetigate the relationship between clinical features of UC and the appearance of PG and its association with ANCA. PATIENTS AND METHODS: ANCA was determined in sera from eight patients with PG. Four out of eight patients had pyoderma gangrenosum associated-UC, and in four cases no identified systemic disease was associated. RESULTS: The search for ANCA yielded negative results in sera from all four patients with pyoderma not associated with systemic disease. Two cases with active and extensive colitis associated with PG and primary sclerosing cholangitis (PSC) were positive for ANCA. Sera from two other patients with both UC and PG had negative test results. CONCLUSIONS: The presence of ANCA in patients with PG associated with UC and PSC suggests that its association with PSC is responsible for ANCA positivity in this subset of patients.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Biological therapy in the treatment of moderate-to-severe ulcerative colitis patients: can colectomy be prevented?
    (Sociedade Brasileira de Coloproctologia, 2011-12-01) Teixeira, Fábio Vieira; Hossne, Rogério Saad; Kotze, Paulo Gustavo; Denadai, Rafael; Miszputen, Sender Jankiel [UNIFESP]; University of the State of São Paulo Botucatu Medical School Department of Surgery; Associação Beneficente Hospital Universitário and Clínica Gastrosaúde; Pontifícia Universidade Católica Department of Surgery; Hospital Universitário Cajuru Colorectal Unit; Universidade Federal de São Paulo (UNIFESP)
    Ulcerative colitis treatment intends to induce remission, and its maintenance. Biological drugs, such as infliximab, have been indicated in moderate and severe cases of the disease, which are unresponsive to conventional medication. Randomized controlled trials proved the efficacy of biological treatment with high rates of sustained disease remission and mucosal healing. Recently, the concept of mucosal healing has been inversely associated with surgical treatment. Patients treated with infliximab have lower colectomy rates than those receiving conventional therapies. We suppose that earlier use of biological drugs in disease's course would lead to better clinical control and mucosal healing, with a consequent reduction in colectomy rates. To support this hypothesis, a literature review from January, 1996 to April, 2011 was performed.